BPC-157/TB-500 10MG

Description

BPC-157/TB-500 10mg blend — research peptide, Canada

Researched & reviewed by the SPO Quality Team · Last reviewed: 30 September 2026

This vial co-formulates two peptides that are usually studied apart. BPC-157 is a 15-residue fragment (GEPPPGKPADDAGLV) of a gastric-juice protein first characterised in 1993^[1]; TB-500 is a trade name covering thymosin β4 (43 residues) or its acetylated 17–23 fragment^[8]. Nearly all the published work is in rats, mice or cell culture, and one study has tested them together^[6]. The powder is supplied for laboratory research only.

Full research overviews, study tables & references → BPC-157 research guide · TB-500 research guide

Identity at a glance

This batch: certificate of analysis

Product tested	BPC/TB blend, declared 10 mg (this listing)
Testing laboratory	Testides (independent)
Report number	JWAY-BPCTB-10-062226
Dates	Received and tested 29 July 2026; reported 14 August 2026
Total mass measured	11.67 mg per vial (116.7% of the 10 mg declaration)
Component content	BPC-157 5.77 mg · TB-500 5.90 mg
Purity (HPLC-UV, 214 nm)	98.75%
Appearance	White lyophilized powder
Report	Open the report (PDF) · COA library

Read a blend report component by component: the purity figure covers the whole chromatogram, and the two masses in the notes give the ratio (blend COA guide). Match the batch on your label to this document; the 20 mg blend has its own paperwork.

What researchers have looked at

• BPC-157, rat Achilles tendon (2003): after transection, treated rats had higher failure load and better function than saline controls, while the peptide did not change cultured tendocyte growth^[2].
• BPC-157, blood vessels (2017): more vessel formation in chick CAM and endothelial-tube assays, faster flow recovery after rat hind-limb ischaemia, and VEGFR2 up-regulation with Akt–eNOS signalling in cultured endothelial cells^[3].
• Thymosin β4 / TB-500, angiogenesis and wounds: the seven-residue actin-binding motif carried the endothelial migration and sprouting activity in vitro^[4]; in rat full-thickness wounds, thymosin β4 sped re-epithelialisation and raised collagen and vessel counts^[5].
• The two together (2026): in 32 rats with a repaired Achilles transection, TB-500 alone improved load to failure and histology versus controls, BPC-157 alone showed numerically better histology, and the combination was no better than either — the authors call the work exploratory^[6].
• Limits: a 2025 systematic review found 35 preclinical BPC-157 studies against one retrospective clinical report and no clinical safety data^[7]; TB-500 products were identified in doping-control work as containing Ac-LKKTETQ, a suspected doping agent^[8]. No human evidence exists for the blend.

Storage and handling

• Keep the sealed vial at −20 °C for long-term storage (the site’s guidance: up to 24 months as dry powder); cool, dry and dark for short periods; no repeated freeze–thaw.
• Both peptides dissolve in water; the rat studies cited above used saline^{[2, 6]}. Sterile or bacteriostatic water is the usual laboratory alternative. Once dissolved, this is a two-analyte sample.

Also listed: BPC-157/TB-500 20MG · BPC-157 5MG · TB-500 5MG. Ships from inside Canada by Canada Post; the shipping policy has dispatch cut-offs, delivery times and the free-shipping threshold. The full catalogue is on our buy peptides online in Canada page.

Frequently asked questions

What is in the BPC-157/TB-500 10mg vial?

Two synthetic peptides co-formulated as one lyophilized powder. The Testides report for this batch (JWAY-BPCTB-10-062226) measured 5.77 mg BPC-157 and 5.90 mg TB-500, 11.67 mg in total against a 10 mg declaration, at 98.75% purity by HPLC-UV. The report does not say whether the TB-500 component is full-length thymosin β4 or the Ac-LKKTETQ fragment.

Is there research on BPC-157 and TB-500 used together?

Very little. One 2026 rat Achilles-tendon study compared each peptide alone with the combination and found the combination gave no additional benefit over either agent (PMID 42542926). Everything else in the literature concerns the two peptides separately, in rodents and cell culture.

How is this blend batch verified?

By an independent laboratory (Testides), which reported HPLC-UV purity and content at 214 nm and listed each component’s mass separately. The report is in the COA library as a PDF; match the batch on your label to it. A report for the 20 mg blend is a different document and does not cover this vial.

Is the BPC-157/TB-500 blend for human use?

No. Neither peptide has an approved product in Canada, the US or the EU; a 2025 systematic review of BPC-157 found no clinical safety data (PMID 40756949), and TB-500 is described in the doping-control literature as a suspected doping agent (PMID 22962027). The vial is supplied for laboratory research only, with no dosing or administration guidance.

Cited

1. Sikirić et al. (1993), Journal of physiology, Paris — PMID 8298609
2. Staresinic et al. (2003), Journal of orthopaedic research : official publication of the Orthopaedic Research Society — PMID 14554208
3. Hsieh et al. (2017), Journal of molecular medicine (Berlin, Germany) — PMID 27847966
4. Philp et al. (2003), FASEB journal : official publication of the Federation of American Societies for Experimental Biology — PMID 14500546
5. Malinda et al. (1999), The Journal of investigative dermatology — PMID 10469335
6. Biçer et al. (2026), Joint diseases and related surgery — PMID 42542926
7. Vasireddi et al. (2025), HSS journal : the musculoskeletal journal of Hospital for Special Surgery — PMID 40756949
8. Esposito et al. (2012), Drug testing and analysis — PMID 22962027

For laboratory research use only. Not for human or animal consumption. No dosing, administration or protocol information is provided, and nothing here is a claim of efficacy or safety in humans.